Skip to content
Menu

TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.

TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.

Read at benzinga.com

← All stock news